Lv41
512 积分 2024-06-13 加入
Treating NASH by targeting peroxisome proliferator-activated receptors
22天前
已完结
Endocrine Adverse Reactions of Tyrosine Kinase Inhibitors in Combination With Immune Checkpoint Inhibitors
28天前
已完结
Peroxisome proliferator-activated receptors in the pathogenesis and therapies of liver fibrosis
1个月前
已完结
Comparative efficacy of THR-β agonists, FGF-21 analogues, GLP-1R agonists, GLP-1-based polyagonists, and Pan-PPAR agonists for MASLD: A systematic review and network meta-analysis
1个月前
已完结
Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors
1个月前
已完结
Non-alcoholic fatty liver disease
1个月前
已完结
2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis
1个月前
已完结
The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis
1个月前
已完结
Clinical characteristics, treatment patterns, and persistence in individuals with type 2 diabetes initiating a glucagon‐like peptide‐1 receptor agonist: A retrospective analysis of the Diabetes Prospective Follow‐Up Registry
1个月前
已完结
The effects of SGLT2 inhibitors and GLP-1 receptor agonists on the triglyceride to HDL cholesterol ratio and the triglyceride-glucose index in patients with type 2 diabetes
1个月前
已完结
皖公网安备34019202002308
